Briefing
Circulating tumor DNA dynamics in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assay.
Serial ctDNA was measured with a whole-genome tumor-informed assay in stage II-III hormone receptor-positive, HER2-negative early breast cancer and examined against recurrence. A Personalis author affiliation is on the PubMed record.
- Design: Evidence level 3
- Assay: Personalis